{Reference Type}: Case Reports
{Title}: Persisting SARS-CoV-2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature.
{Author}: Tepasse PR;Hafezi W;Lutz M;Kühn J;Wilms C;Wiewrodt R;Sackarnd J;Keller M;Schmidt HH;Vollenberg R;
{Journal}: Br J Haematol
{Volume}: 190
{Issue}: 2
{Year}: 07 2020
{Factor}: 8.615
{DOI}: 10.1111/bjh.16896
{Abstract}: SARS-CoV-2 infection can cause severe pneumonia (COVID-19). There is evidence that patients with comorbidities are at higher risk of a severe disease course. The role of immunosuppression in the disease course is not clear. In the present report, we first describe two cases of persisting SARS-CoV-2 viraemia with fatal outcome in patients after rituximab therapy.